Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

Eli Lilly (LLY) announced positive Phase 3 trial results for its oral GLP-1 receptor agonist, orforglipron, demonstrating significant A1C reduction (1.3% to 1.6%) and weight loss (7.9% at the highest dose) in adults with type 2 diabetes. The ACHIEVE-1 trial, published in The New England Journal of Medicine, showed orforglipron's safety profile was consistent with injectable GLP-1s, with gastrointestinal-related adverse events being the most common. These results position orforglipron as a potential oral alternative to injectable GLP-1 therapies, with regulatory submissions planned for weight management by year-end and type 2 diabetes in 2026.

Analysis

Eli Lilly's Phase 3 ACHIEVE-1 trial results for orforglipron present a significant positive development, reinforcing the company's formidable position in the GLP-1 market. The investigational once-daily oral drug demonstrated compelling efficacy, achieving a superior A1C reduction of 1.3% to 1.6% from an 8.0% baseline and a meaningful secondary endpoint of 7.9% (16.0 lbs) weight loss at the highest dose. Critically, orforglipron's profile as a small molecule pill without food or water restrictions presents a key convenience advantage over existing oral GLP-1 competitors, potentially expanding its addressable market to patients averse to injectables or complex dosing regimens. The safety profile was consistent with the established GLP-1 class, characterized by manageable gastrointestinal adverse events and low treatment discontinuation rates (4-8%), which de-risks its path to approval. With regulatory submissions planned for weight management by the end of 2025 and for type 2 diabetes in 2026, and with head-to-head trial data against oral semaglutide expected later this year, these results position orforglipron as a potentially highly competitive asset in Lilly's metabolic franchise.

Key Decisions for Investors

• The positive Phase 3 data significantly de-risks orforglipron's development path and strengthens the long-term growth thesis for Eli Lilly, supporting a continued overweight or buy rating on the stock.
• Investors should closely monitor the upcoming results from the ACHIEVE trials comparing orforglipron against oral semaglutide, as superior efficacy or convenience data could be a major catalyst for re-rating Lilly's future market share in the oral obesity and diabetes segment.
• Consider the drug's convenient dosing regimen as a key factor in market adoption, as its lack of food and water restrictions could capture a substantial patient population currently hesitant to use existing GLP-1 therapies.
• While the safety profile appears favorable and in line with the class, pay attention to the tolerability data in future, larger trials, as this will be a crucial competitive factor against other oral and injectable treatments.